David Drenning, MD
Interventional Cardiology · Huntsville, ALNPI 1437129152
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Novartis accounts for 60.2% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2019 at $18,998 and has fallen 92.9% since, to $1,357 in 2025.
Across 632 payments — averaging $49.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$19K
- Medtronic$2K
- Johnson & Johnson$1K
- Amgen$1K
- AstraZeneca$949
- Boston Scientific$859
- plus $6K from 27 others
What the payments were for
- Speaking & faculty fees$15,90051%
- Travel & lodging$1,2374%
- Food & beverage$13,88445%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 142 | $18,668 |
| Medtronic(2 entities) | 26 | $2,390 |
| Johnson & Johnson | 80 | $1,299 |
| Amgen | 68 | $1,278 |
| AstraZeneca | 37 | $949 |
| Boston Scientific | 14 | $859 |
| Boehringer Ingelheim | 30 | $650 |
| Abbott | 11 | $630 |
| Pfizer | 38 | $624 |
| E.r. Squibb & Sons, L.L.C. | 30 | $618 |
| Regeneron Healthcare Solutions, Inc. | 19 | $406 |
| Sanofi-aventis U.S. LLC | 20 | $369 |
| Merck | 17 | $357 |
| Novo Nordisk | 19 | $351 |
| Bayer | 15 | $301 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $284 |
| Esperion Therapeutics, Inc. | 11 | $233 |
| United Therapeutics Corporation | 5 | $154 |
| Gilead | 12 | $143 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| Cardiovascular Systems Inc. | 6 | $67 |
| Abiomed | 2 | $44 |
| Actelion Pharmaceuticals US, Inc. | 2 | $44 |
| Terumo Medical Corporation | 2 | $36 |
| Cvrx, Inc. | 1 | $33 |
| Scpharmaceuticals Inc. | 2 | $33 |
| GE HealthCare | 2 | $25 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Chiesi USA, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Recor Medical Inc | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$16,254
- Resolute$1,616
- AVVIGO Guidance System$366
- Optis Coronary Imaging System$278
- WATCHMAN Access System$152
- Repatha$125
- FARXIGA$125
- MitraClip System$124
- RESONATE EL ICD VR$106
How this compares
$31,036 in reported general payments places this provider in the 80th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 411 | $419,394 |
| EntrestoSacubitril/Valsartan | 166 | $189,179 |
| XareltoRivaroxaban | 174 | $150,893 |
| Repatha SureclickEvolocumab | 106 | $102,028 |
| JardianceEmpagliflozin | 49 | $62,173 |
| FarxigaDapagliflozin Propanediol | 52 | $45,905 |
| MultaqDronedarone Hcl | 31 | $43,292 |
| Praluent PenAlirocumab | 25 | $14,136 |
| Metoprolol Succinate | 588 | $10,901 |
| BrilintaTicagrelor | 20 | $10,282 |
| LivaloPitavastatin Calcium | 13 | $8,594 |
| Rosuvastatin Calcium | 356 | $6,483 |
| Atorvastatin Calcium | 359 | $6,383 |
| Prasugrel Hcl | 39 | $4,401 |
| ClopidogrelClopidogrel Bisulfate | 267 | $3,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $624 | $419,394411 claims |
| NovartisEntresto | $18,668 | $189,179166 claims |
| Johnson & JohnsonXarelto | $1,299 | $150,893174 claims |
| Boehringer IngelheimJardiance | $650 | $62,17349 claims |
| AstraZenecaFarxiga, Brilinta | $949 | $56,18672 claims |
| Sanofi-aventis U.S. LLCMultaq | $369 | $43,29231 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $12 | $8,59413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Huntsville
- Michael ButlerHuntsville$109K
- Pochana ReddyHuntsville$100K
- Alejandro VasquezHuntsville$45K
- Clarence GillHuntsville$13K
- Victor OkunrintemiHuntsville$12K
- Henry ChenHuntsville$8K
- Mihir KanitkarHuntsville$7K
- Gary RoubinBirmingham$157K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.